The efficacy of pindolol in reducing weight gain associated with the use of Olanzapine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87255415

Enrollment

Registered

2003-09-12

Start date

2002-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Nutritional, Metabolic, Endocrine

Interventions

Randomised controlled trial: A. Olanzapine treatment in combination with pinadolol B. Olazapine treatment alone

Eligibility

Inclusion criteria

Inclusion criteria: 36 Participants, who will be recruited through the clinicians working with Camden and Islington Mental Health and Social Care Trust.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Olanzapine is commonly used in the treatment of schizophrenia. Whilst generally well tolerated, weight gain is known to effect compliance and acceptability to many patients. In patients who continue to take Olanzapine despite gaining weight there are general health and psychological ramifications. If weight gain could be minimised then this burden may be reduced, leading to a lessening of pressure upon NHS resources.	—

Measure

Time frame

Olanzapine is commonly used in the treatment of schizophrenia. Whilst generally well tolerated, weight gain is known to effect compliance and acceptability to many patients. In patients who continue to take Olanzapine despite gaining weight there are general health and psychological ramifications. If weight gain could be minimised then this burden may be reduced, leading to a lessening of pressure upon NHS resources.

—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026